This is a medical procedure where a person receives lymphocytes, which are a type of white blood cell, from another person. This might be done in specific medical situations.
Every report comes from a Lived member, sent anonymously.
Have you had Lymphocyte Transfusion for AML (Acute Myeloid Leukemia)?
A lymphocyte transfusion gives a person lymphocytes, the white blood cells that direct much of the immune system's attack on infections and abnormal cells. In practice the term almost always means a donor lymphocyte infusion (DLI): lymphocytes collected from the same person who donated stem cells for an earlier allogeneic (donor) stem cell transplant are infused into the transplant recipient. The donor's immune cells can recognize leftover cancer cells as foreign and attack them, which specialists call the graft-versus-leukemia or graft-versus-tumor effect. DLI is a form of immunotherapy, and it only makes sense for someone who has already had a donor transplant. Its main job is dealing with blood cancers that come back, or threaten to come back, after transplant. It can be given to treat a relapse that has already been found, often after a round of chemotherapy to reduce the amount of cancer first. It can be given pre-emptively when sensitive tests show traces of disease (measurable residual disease) or show that the bone marrow holds a mix of the patient's own cells and donor cells (mixed chimerism), a pattern linked to a higher chance of relapse. Some centers also give it preventively to people at high risk of relapse. How well it works depends heavily on the disease. In chronic myeloid leukemia that relapses after transplant, most people go into complete remission with DLI. Fewer than 4 in 10 people with relapsed acute leukemia respond, and long-term survival after an acute leukemia relapse remains low even with treatment. It is also used in myeloma and studied in other blood cancers. Compared with a second transplant, DLI appears to give similar results with fewer treatment-related deaths, so it is often the first option a transplant team considers.
The decision starts with the transplant team checking where the disease stands and whether DLI is safe right now. Typical tests include blood counts, kidney and liver function tests and often a bone marrow biopsy to measure remaining cancer and the mix of donor and patient cells. If there is a large amount of cancer, chemotherapy or another cancer drug usually comes first. Active severe graft-versus-host disease, a serious infection or poorly working organs can make DLI unsafe until they are under control. The lymphocytes come from the original stem cell donor. Sometimes cells were frozen and stored at the time of the first donation, so no new collection is needed. Otherwise the donor gives blood through a process called apheresis, in which a machine draws blood from a vein, separates out the lymphocyte-rich cells and returns the rest of the blood. The team explains the plan in advance, including the starting dose and whether more doses may follow.
The infusion itself is simple and resembles a blood transfusion. The cells run into a vein through an IV (a thin tube placed in a vein) or through an existing central line, a longer catheter that sits in a large vein in the chest. It usually takes no more than about 30 minutes and does not need sedation. Nurses check temperature, blood pressure and breathing during and after the infusion. If the cells were frozen, they are thawed just before use. The preservative used for freezing can cause a brief reaction or a strange smell, which the team watches for. Many people receive more than one infusion, often at gradually increasing doses spaced several weeks apart, because starting lower lowers the risk of graft-versus-host disease without clearly reducing benefit.
Most people go home the same day and can return to their usual routine, but the important part of DLI unfolds over the following weeks and months. The donor cells need time to work, and when the cancer responds, the response usually appears within about two to three months. Regular clinic visits and blood tests track blood counts, the share of donor cells in the marrow, signs of disease and any early graft-versus-host disease. Repeat bone marrow tests may be needed. The results of each check guide whether another dose is given, the dose raised or the treatment stopped. Contact the transplant team right away for a fever, unusual bleeding or bruising, shortness of breath, or possible signs of graft-versus-host disease such as a new skin rash, diarrhea, or yellowing of the skin or eyes. These problems are easier to treat when caught early.
The main risk is graft-versus-host disease (GVHD), the same reaction that can follow a donor transplant. The donor lymphocytes that attack cancer can also attack healthy tissue, most often the skin, gut and liver. It can be mild or severe, and short-lived or long-lasting. The risk is higher when DLI is given soon after transplant, at a higher cell dose or from a half-matched (haploidentical) donor. GVHD is treated with medicines that calm the immune system, which can also blunt the anticancer effect, so the team balances the two. DLI can also lower blood counts, sometimes severely, a problem called marrow aplasia. This is mainly a concern when DLI treats an established relapse and is uncommon with preventive or pre-emptive doses. Low counts can cause fatigue, bleeding and infection, and infections, particularly viral and fungal ones, are among the most serious complications after GVHD or low counts. Low counts often recover on their own or with transfusions and growth-factor medicines. DLI does not always work, and some relapses are unlikely to respond. For example, after a half-matched transplant, some leukemias escape by losing the mismatched immune markers that donor cells recognize, and a different approach may be needed. Much of what doctors know about timing and dosing comes from observational studies and expert consensus rather than randomized trials, so practice varies between centers.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience with Lymphocyte Transfusion, what to expect, or ask the community a question.